Best Practice & Research Clinical Endocrinology & Metabolism
Volume 23, Issue 6 , Pages 703-712 , December 2009

Interferon induced thyroiditis

  • Yaron Tomer, Professor

      Affiliations

    • Department of Medicine, Division of Endocrinology, Mount Sinai School of Medicine, New York, NY, USA
    • James J. Peters VA Medical Center, New York, NY, USA
    • Corresponding Author InformationCorresponding author. Department of Medicine, Division of Endocrinology, Mount Sinai School of Medicine, Box 1118, One Gustave L. Levy Place, New York, NY 10029, USA. Tel.: +1 212 241 6834; Fax: +1 212 534 3488.
    • ,
  • Francesca Menconi, Post-doctoral Fellow

      Affiliations

    • Division of Endocrinology, Mount Sinai Medical Center, New York, NY, USA

References 

  1. Pfeffer LM, Dinarello CA, Herberman RB, et al. Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons. Cancer Research. 1998;58(12):2489–2499
  2. Parmar S, Platanias LC. Interferons: mechanisms of action and clinical applications. Current Opinion in Oncology. 2003;15(6):431–439
  3. Jonasch E, Haluska FG. Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. Oncologist. 2001;6(1):34–55
  4. Baron S, Tyring SK, Fleischmann WR, et al. The interferons. Mechanisms of action and clinical applications. The Journal of the American Medical Association. 1991;266(10):1375–1383
  5. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. New England Journal of Medicine. 2002;347(13):975–982
  6. Russo MW, Fried MW. Side effects of therapy for chronic hepatitis C. Gastroenterology. 2003;124(6):1711–1719
  7. Fentiman IS, Thomas BS, Balkwill FR, et al. Primary hypothyroidism associated with interferon therapy of breast cancer. Lancet. 1985;1(8438):1166
  8. Prummel MF, Laurberg P. Interferon-alpha and autoimmune thyroid disease. Thyroid. 2003;13(6):547–551
  9. Koh LK, Greenspan FS, Yeo PP. Interferon-alpha induced thyroid dysfunction: three clinical presentations and a review of the literature. Thyroid. 1997;7(6):891–896
  10. Roti E, Minelli R, Giuberti T, et al. Multiple changes in thyroid function in patients with chronic active HCV hepatitis treated with recombinant interferon-alpha. American Journal of Medicine. 1996;101(5):482–487
  11. Mazziotti G, Sorvillo F, Stornaiuolo G, et al. Temporal relationship between the appearance of thyroid autoantibodies and development of destructive thyroiditis in patients undergoing treatment with two different type-1 interferons for HCV-related chronic hepatitis: a prospective study. Journal of Endocrinological Investigation. 2002;25(7):624–630
  12. Mandac JC, Chaudhry S, Sherman KE, et al. The clinical and physiological spectrum of interferon-alpha induced thyroiditis: toward a new classification. Hepatology. 2006;43(4):661–672
  13. Martocchia A, Labbadia G, Paoletti V, et al. Hashimoto's disease during interferon-alpha therapy in a patient with pre-treatment negative anti-thyroid autoantibodies and with the specific genetic susceptibility to the thyroid disease. Neuro Endocrinology Letters. 2001;22(1):49–52
  14. Baudin E, Marcellin P, Pouteau M, et al. Reversibility of thyroid dysfunction induced by recombinant alpha interferon in chronic hepatitis C. Clinical Endocrinology. 1993;39(6):657–661
  15. Carella C, Mazziotti G, Morisco F, et al. Long-term outcome of interferon-alpha-induced thyroid autoimmunity and prognostic influence of thyroid autoantibody pattern at the end of treatment. The Journal of Clinical Endocrinology and Metabolism. 2001;86(5):1925–1929
  16. Watanabe U, Hashimoto E, Hisamitsu T, et al. The risk factor for development of thyroid disease during interferon-alpha therapy for chronic hepatitis C. The American Journal of Gastroenterology. 1994;89(3):399–403
  17. Preziati D, La Rosa L, Covini G, et al. Autoimmunity and thyroid function in patients with chronic active hepatitis treated with recombinant interferon alpha-2a. European Journal of Endocrinology. 1995;132(5):587–593
  18. Imagawa A, Itoh N, Hanafusa T, et al. Autoimmune endocrine disease induced by recombinant interferon-alpha therapy for chronic active type C hepatitis. The Journal of Clinical Endocrinology and Metabolism. 1995;80(3):922–926
  19. Wong V, Fu AX, George J, et al. Thyrotoxicosis induced by alpha-interferon therapy in chronic viral hepatitis. Clinical Endocrinology. 2002;56(6):793–798
  20. Lisker-Melman M, Di Bisceglie AM, Usala SJ, et al. Development of thyroid disease during therapy of chronic viral hepatitis with interferon alfa. Gastroenterology. 1992;102(6):2155–2160
  21. Villanueva RB, Brau N. Graves' ophthalmopathy associated with interferon-alpha treatment for hepatitis C. Thyroid. 2002;12(8):737–738
  22. Hollowell JG, Staehling NW, Flanders WD, et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). The Journal of Clinical Endocrinology and Metabolism. 2002;87(2):489–499
  23. Vanderpump MPJ, Tunbridge WMG, French JM, et al. The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham survey. Clinical Endocrinology. 1995;43:55–68
  24. Ban Y, Greenberg DA, Davies TF, et al. Linkage analysis of thyroid antibody production: evidence for shared susceptibility to clinical autoimmune thyroid disease. The Journal of Clinical Endocrinology and Metabolism. 2008;93(9):3589–3596
  25. Carella C, Amato G, Biondi B, et al. Longitudinal study of antibodies against thyroid in patients undergoing interferon-alpha therapy for HCV chronic hepatitis. Hormone Research. 1995;44(3):110–114
  26. Marazuela M, Garcia-Buey L, Gonzalez-Fernandez B, et al. Thyroid autoimmune disorders in patients with chronic hepatitis C before and during interferon-alpha therapy. Clinical Endocrinology. 1996;44(6):635–642
  27. Weetman AP, Smallridge RC, Nutman TB, et al. Persistent thyroid autoimmunity after subacute thyroiditis. Journal of Clinical & Laboratory Immunology. 1987;23:1–6
  28. Parana R, Cruz M, Lyra L, et al. Subacute thyroiditis during treatment with combination therapy (interferon plus ribavirin) for hepatitis C virus. Journal of Viral Hepatitis. 2000;7(5):393–395
  29. Bohbot NL, Young J, Orgiazzi J, et al. Interferon-alpha-induced hyperthyroidism: a three-stage evolution from silent thyroiditis towards Graves' disease. European Journal of Endocrinology. 2006;154(3):367–372
  30. Nguyen KB, Watford WT, Salomon R, et al. Critical role for STAT4 activation by type 1 interferons in the interferon-gamma response to viral infection. Science. 2002;297(5589):2063–2066
  31. Corssmit EP, de Metz J, Sauerwein HP, et al. Biologic responses to IFN-alpha administration in humans. Journal of Interferon & Cytokine Research. 2000;20(12):1039–1047
  32. You X, Teng W, Shan Z. Expression of ICAM-1, B7.1 and TPO on human thyrocytes induced by IFN-alpha. Chinese Medical Journal. 1999;112(1):61–66
  33. Farrar JD, Murphy KM. Type I interferons and T helper development. Immunology Today. 2000;21(10):484–489
  34. Tilg H. New insights into the mechanisms of interferon alfa: an immunoregulatory and anti-inflammatory cytokine. Gastroenterology. 1997;112(3):1017–1021
  35. Mazziotti G, Sorvillo F, Piscopo M, et al. Innate and acquired immune system in patients developing interferon-alpha-related autoimmune thyroiditis: a prospective study. The Journal of Clinical Endocrinology and Metabolism. 2005;90(7):4138–4144
  36. Land KJ, Moll JS, Kaplan MH, et al. Signal transducer and activator of transcription (Stat)-6-dependent, but not Stat4-dependent, immunity is required for the development of autoimmunity in Graves' hyperthyroidism. Endocrinology. 2004;145(8):3724–3730
  37. Mazziotti G, Sorvillo F, Carbone A, et al. Is the IFN-alpha-related thyroid autoimmunity an immunologically heterogeneous disease?. Journal of Internal Medicine. 2002;252(4):377–378
  38. Nagayama Y, Mizuguchi H, Hayakawa T, et al. Prevention of autoantibody-mediated Graves'-like hyperthyroidism in mice with IL-4, a Th2 cytokine. Journal of Immunology. 2003;170(7):3522–3527
  39. Corssmit EP, Heijligenberg R, Hack CE, et al. Effects of interferon-alpha (IFN-alpha) administration on leucocytes in healthy humans. Clinical and Experimental Immunology. 1997;107(2):359–363
  40. Ajjan RA, Watson PF, McIntosh RS, et al. Intrathyroidal cytokine gene expression in Hashimoto's thyroiditis. Clinical and Experimental Immunology. 1996;105(3):523–528
  41. Krause I, Valesini G, Scrivo R, et al. Autoimmune aspects of cytokine and anticytokine therapies. American Journal of Medicine. 2003;115(5):390–397
  42. Lindahl P, Leary P, Gresser I. Enhancement by interferon of the expression of surface antigens on murine leukemia L 1210 cells. Proceedings of the National Academy of Sciences of the United States of America. 1973;70(10):2785–2788
  43. Caraccio N, Giannini R, Cuccato S, et al. Type I interferons modulate the expression of thyroid peroxidase, sodium/iodide symporter, and thyroglobulin genes in primary human thyrocyte cultures. The Journal of Clinical Endocrinology and Metabolism. 2005;90(2):1156–1162
  44. Akeno N, Tomer Y. Dissecting the mechanisms of interferon induced thyroiditis (IIT): direct effects of interferon alpha on thyroid epithelial cells. The 89th meeting of the Endocrine Society, Toronto, Canada, June 2007. 2007.
  45. Caraccio N, Cuccato S, Pratesi F, et al. Effect of type I interferon(s) on cell viability and apoptosis in primary human thyrocyte cultures. Thyroid. 2009;19(2):149–155
  46. Kryczka W, Brojer E, Kowalska A, et al. Thyroid gland dysfunctions during antiviral therapy of chronic hepatitis C. Medical Science Monitor. 2001;7(Suppl. 1):221–225
  47. Deutsch M, Koskinas J, Tzannos K, et al. Hashimoto encephalopathy with pegylated interferon alfa-2b and ribavirin. The Annals of Pharmacotherapy. 2005;39(10):1745–1747
  48. Rotondi M, Minelli R, Magri F, et al. Serum CXCL10 levels and occurrence of thyroid dysfunction in patients treated with interferon-{alpha} therapy for hepatitis C virus-related hepatitis. European Journal of Endocrinology. 2007;156(4):409–414
  49. Weetman AP. Graves' disease. New England Journal of Medicine. 2000;343(17):1236–1248
  50. Tomer Y, Davies TF. Searching for the autoimmune thyroid disease susceptibility genes: from gene mapping to gene function. Endocrine Reviews. 2003;24:694–717
  51. Huber A, Menconi F, Corathers S, et al. Joint genetic susceptibility to type 1 diabetes and autoimmune thyroiditis: from epidemiology to mechanisms. Endocrine Reviews. 2008;29(6):697–725
  52. Dalgard O, Bjoro K, Hellum K, et al. Thyroid dysfunction during treatment of chronic hepatitis C with interferon alpha: no association with either interferon dosage or efficacy of therapy. Journal of Internal Medicine. 2002;251(5):400–406
  53. Grossman CJ, Roselle GA, Mendenhall CL. Sex steroid regulation of autoimmunity. The Journal of Steroid Biochemistry and Molecular Biology. 1991;40(4–6):649–659
  54. Oppenheim Y, Kim G, Ban Y, et al. The effects of alpha interferon on the development of autoimmune thyroiditis in the NOD H2h4 mouse. Clinical & Developmental Immunology. 2003;10(2-4):161–165
  55. Jacobson EM, Tomer Y. The CD40, CTLA-4, thyroglobulin, TSH receptor, and PTPN22 gene quintet and its contribution to thyroid autoimmunity: back to the future. Journal of Autoimmunity. 2007;28:85–98
  56. Stenszky V, Kozma L, Balazs C, et al. The genetics of Graves' disease: HLA and disease susceptibility. The Journal of Clinical Endocrinology and Metabolism. 1985;61:735–740
  57. Ban Y, Davies TF, Greenberg DA, et al. Arginine at position 74 of the HLA-DRb1 chain is associated with Graves' disease. Genes and Immunity. 2004;5:203–208
  58. Yanagawa T, Hidaka Y, Guimaraes V, et al. CTLA-4 gene polymorphism associated with Graves' disease in a caucasian population. The Journal of Clinical Endocrinology and Metabolism. 1995;80:41–45
  59. Vaidya B, Imrie H, Perros P, et al. The cytotoxic T lymphocyte antigen-4 is a major Graves' disease locus. Human Molecular Genetics. 1999;8(7):1195–1199
  60. Tomer Y, Greenberg DA, Barbesino G, et al. CTLA-4 and not CD28 is a susceptibility gene for thyroid autoantibody production. The Journal of Clinical Endocrinology and Metabolism. 2001;86:1687–1693
  61. Smyth D, Cooper JD, Collins JE, et al. Replication of an association between the lymphoid tyrosine phosphatase locus (LYP/PTPN22) with type 1 diabetes, and evidence for its role as a general autoimmunity locus. Diabetes. 2004;53(11):3020–3023
  62. Velaga MR, Wilson V, Jennings CE, et al. The codon 620 tryptophan allele of the lymphoid tyrosine phosphatase (LYP) gene is a major determinant of Graves' disease. The Journal of Clinical Endocrinology and Metabolism. 2004;89(11):5862–5865
  63. Ban Y, Greenberg DA, Concepcion E, et al. Amino acid substitutions in the thyroglobulin gene are associated with susceptibility to human and murine autoimmune thyroid disease. Proceedings of the National Academy of Sciences of the United States of America. 2003;100:15119–15124
  64. Hiratani H, Bowden DW, Ikegami S, et al. Multiple SNPs in intron 7 of thyrotropin receptor are associated with Graves' disease. The Journal of Clinical Endocrinology and Metabolism. 2005;90(5):2898–2903
  65. Kakizaki S, Takagi H, Murakami M, et al. HLA antigens in patients with interferon-alpha-induced autoimmune thyroid disorders in chronic hepatitis C. Journal of Hepatology. 1999;30(5):794–800
  66. Jacobson EM, Chaudhry S, Mandac JC, et al. Immune-regulatory gene involvement in the etiology of interferon induced thyroiditis (IIT). Thyroid. 2006;16:926
  67. Oppenheim Y, Ban Y, Tomer Y. Interferon induced Autoimmune Thyroid Disease (AITD): a model for human autoimmunity. Autoimmunity Reviews. 2004;3(5):388–393
  68. Tomer Y, Davies TF. Infection, thyroid disease and autoimmunity. Endocrine Reviews. 1993;14:107–120
  69. Tomer Y, Villanueva R. Hepatitis C and thyroid autoimmunity: is there a link?. American Journal of Medicine. 2004;117(1):60–61
  70. Loviselli A, Oppo A, Velluzzi F, et al. Independent expression of serological markers of thyroid autoimmunity and hepatitis virus C infection in the general population: results of a community-based study in north-western Sardinia. Journal of Endocrinological Investigation. 1999;22(9):660–665
  71. Metcalfe RA, Ball G, Kudesia G, et al. Failure to find an association between hepatitis C virus and thyroid autoimmunity. Thyroid. 1997;7(3):421–424
  72. Boadas J, Rodriguez-Espinosa J, Enriquez J, et al. Prevalence of thyroid autoantibodies is not increased in blood donors with hepatitis C virus infection. Journal of Hepatology. 1995;22(6):611–615
  73. Tran A, Quaranta JF, Benzaken S, et al. High prevalence of thyroid autoantibodies in a prospective series of patients with chronic hepatitis C before interferon therapy. Hepatology. 1993;18(2):253–257
  74. Ganne-Carrie N, Medini A, Coderc E, et al. Latent autoimmune thyroiditis in untreated patients with HCV chronic hepatitis: a case-control study. Journal of Autoimmunity. 2000;14(2):189–193
  75. Fernandez-Soto L, Gonzalez A, Escobar-Jimenez F, et al. Increased risk of autoimmune thyroid disease in hepatitis C vs hepatitis B before, during, and after discontinuing interferon therapy. Archives of Internal Medicine. 1998;158(13):1445–1448
  76. Antonelli A, Ferri C, Pampana A, et al. Thyroid disorders in chronic hepatitis C. American Journal of Medicine. 2004;117(1):10–13
  77. Indolfi G, Stagi S, Bartolini E, et al. Thyroid function and anti-thyroid autoantibodies in untreated children with vertically acquired chronic hepatitis C virus infection. Clinical Endocrinology. 2008;68(1):117–121
  78. Antonelli A, Ferri C, Fallahi P, et al. Thyroid disorders in chronic hepatitis C virus infection. Thyroid. 2006;16(6):563–572
  79. Bartolome J, Rodriguez-Inigo E, Quadros P, et al. Detection of hepatitis C virus in thyroid tissue from patients with chronic HCV infection. Journal of Medical Virology. 2008;80(9):1588–1594
  80. Munshi N, Balasubramanian A, Koziel M, et al. Hepatitis C and human immunodeficiency virus envelope proteins cooperatively induce hepatocytic apoptosis via an innocent bystander mechanism. The Journal of Infectious Diseases. 2003;188(8):1192–1204
  81. Balasubramanian A, Ganju RK, Groopman JE. Signal transducer and activator of transcription factor 1 mediates apoptosis induced by hepatitis C virus and HIV envelope proteins in hepatocytes. The Journal of Infectious Diseases. 2006;194(5):670–681
  82. Balasubramanian A, Ganju RK, Groopman JE. Hepatitis C virus and HIV envelope proteins collaboratively mediate interleukin-8 secretion through activation of p38 MAP kinase and SHP2 in hepatocytes. The Journal of Biological Chemistry. 2003;278(37):35755–35766
  83. Akeno N, Blackard JT, Tomer Y. HCV E2 protein binds directly to thyroid cells and induces IL-8 production: a new mechanism for HCV induced thyroid autoimmunity. The Journal of Autoimmunity. 2008;31(4):339–344
  84. Tomer Y, Blackard JT, Akeno N. Interferon alpha treatment and thyroid dysfunction. Endocrinology and Metabolism Clinics of North America. 2007;36(4):1051–1066

PII: S1521-690X(09)00080-3

doi: 10.1016/j.beem.2009.07.004

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 23, Issue 6 , Pages 703-712 , December 2009

Article Tools

* Image Usage & Resolution